Home » Stocks » GRTX

Galera Therapeutics, Inc. (GRTX)

Stock Price: $10.00 USD -0.01 (-0.10%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 249.51M
Revenue (ttm) n/a
Net Income (ttm) -71.82M
Shares Out 24.87M
EPS (ttm) -173.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $10.00
Previous Close $10.01
Change ($) -0.01
Change (%) -0.10%
Day's Open 9.95
Day's Range 9.75 - 10.19
Day's Volume 73,085
52-Week Range 5.89 - 17.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of nov...

GlobeNewsWire - 2 months ago

Presented Promising Interim Data from Placebo-controlled P ilot Dismutase Mimetic SBRT Combination Trial for P ancreatic C ancer

GlobeNewsWire - 2 months ago

MALVERN, Pa., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of nov...

GlobeNewsWire - 2 months ago

Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual Meeting

GlobeNewsWire - 2 months ago

Interim d ata on first 19 patients released in ASTRO Annual Meeting late-breaker presentation abstract showed improvement in overall survival and multiple anti-cancer efficacy measures

GlobeNewsWire - 3 months ago

MALVERN, Pa., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of ...

GlobeNewsWire - 4 months ago

MALVERN, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of ...

Seeking Alpha - 4 months ago

Galera Therapeutics is a promising company backed by prestigious venture firms.

GlobeNewsWire - 5 months ago

Completed Enrollment of Randomized, Blinded, Placebo-controlled Trial of GC4419 in Combination with Radiotherapy in Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H20

GlobeNewsWire - 5 months ago

MALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of n...

GlobeNewsWire - 6 months ago

Topline safety and efficacy data to be reported in the second half of 2020 Topline safety and efficacy data to be reported in the second half of 2020

GlobeNewsWire - 7 months ago

Retrospective analysis of patients with head and neck cancer treated in Phase 2b clinical trial of avasopasem manganese presented at ASCO 2020 Virtual Scientific Program Retrospective analysis...

GlobeNewsWire - 8 months ago

ROMAN Phase 3 Trial Topline Data Readout Guidance Updated to 2H21 Due to Impact of COVID-19

GlobeNewsWire - 8 months ago

MALVERN, Penn., April 30, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline o...

GlobeNewsWire - 10 months ago

MALVERN, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of n...

GlobeNewsWire - 1 year ago

-- Evaluates avasopasem manganese’s ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer -- -- Marks expansion of lead product candidate avasopasem ...

About GRTX

Galera Therapeutics, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer. It ... [Read more...]

Industry
Biotechnology
IPO Date
Nov 7, 2019
CEO
Dr. J. Mel Sorensen
Employees
32
Stock Exchange
NASDAQ
Ticker Symbol
GRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for GRTX stock is "Strong Buy." The 12-month stock price forecast is 19.60, which is an increase of 96.00% from the latest price.

Price Target
$19.60
(96.00% upside)
Analyst Consensus: Strong Buy